Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Parkinson's Disease

  Free Subscription


25.10.2021

2 BMC Neurol
1 Int J Neurosci
5 J Neural Transm (Vienna)
6 Mov Disord
2 Neurochem Res
3 Neurology
2 Neurosci Lett
1 PLoS One
1 Science


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BMC Neurol

  1. ANFORS S, Kammerlind AS, Nilsson MH
    Test-retest reliability of physical activity questionnaires in Parkinson's disease.
    BMC Neurol. 2021;21:399.
    PubMed         Abstract available

  2. EGUCHI K, Shirai S, Matsushima M, Kano T, et al
    Correlation of active contact location with weight gain after subthalamic nucleus deep brain stimulation: a case series.
    BMC Neurol. 2021;21:351.
    PubMed         Abstract available


    Int J Neurosci

  3. KAISEROVA M, Kastelikova A, Grambalova Z, Otruba P, et al
    Temperature sensation in Parkinson's disease measured by quantitative sensory testing: a single-center, case-control study.
    Int J Neurosci. 2021 Oct 19:1-8. doi: 10.1080/00207454.2021.1991922.
    PubMed         Abstract available


    J Neural Transm (Vienna)

  4. GONZALEZ-LATAPI P, Marotta N, Mencacci NE
    Emerging and converging molecular mechanisms in dystonia.
    J Neural Transm (Vienna). 2021;128:483-498.
    PubMed         Abstract available

  5. DANYSZ W, Dekundy A, Scheschonka A, Riederer P, et al
    Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials.
    J Neural Transm (Vienna). 2021;128:127-169.
    PubMed         Abstract available

  6. WINKEL I, Ermann N, Zelwetro A, Sambor B, et al
    Cerebrospinal fluid alpha synuclein concentrations in patients with positive AD biomarkers and extrapyramidal symptoms.
    J Neural Transm (Vienna). 2021;128:817-825.
    PubMed         Abstract available

  7. NAOI M, Maruyama W, Shamoto-Nagai M
    Disease-modifying treatment of Parkinson's disease by phytochemicals: targeting multiple pathogenic factors.
    J Neural Transm (Vienna). 2021 Oct 15. pii: 10.1007/s00702-021-02427.
    PubMed         Abstract available

  8. KITAGAWA T, Umehara T, Oka H, Shiraishi T, et al
    Correction to: Association between heart rate variability and striatal dopamine depletion in Parkinson's disease.
    J Neural Transm (Vienna). 2021 Oct 19. pii: 10.1007/s00702-021-02428.
    PubMed        


    Mov Disord

  9. NAMBU A
    Distinct Roles of the Dorsal Versus Ventral Subthalamic Nucleus.
    Mov Disord. 2021;36:2223.
    PubMed        

  10. KLARENDIC M, Kirbis M, Mojsovska E, Kavcic M, et al
    Bee Venom Does Not Reduce the Risk for Parkinson's Disease: Epidemiological Study among Beekeepers.
    Mov Disord. 2021 Oct 16. doi: 10.1002/mds.28820.
    PubMed         Abstract available

  11. GAN-OR Z, Wood NW
    Mendelian Randomization Studies: A Path to Better Understand Sex and Gender Differences in Parkinson's Disease?
    Mov Disord. 2021;36:2220-2222.
    PubMed        

  12. ONG TL, Dal S, Williams LJ, Morales-Briceno H, et al
    \Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population.
    Mov Disord. 2021;36:2452.
    PubMed        

  13. KANG X, Ploner A, Roelstraete B, Khalili H, et al
    Reply to: "Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population".
    Mov Disord. 2021;36:2453.
    PubMed        

  14. SAMBIN S, Lavisse S, Decaix C, Pyatigorskaya N, et al
    Compensatory Mechanisms Nine Years Before Parkinson's Disease Conversion in a LRRK2 R1441H Family.
    Mov Disord. 2021 Oct 20. doi: 10.1002/mds.28833.
    PubMed        


    Neurochem Res

  15. ROE K
    An Alternative Explanation for Alzheimer's Disease and Parkinson's Disease Initiation from Specific Antibiotics, Gut Microbiota Dysbiosis and Neurotoxins.
    Neurochem Res. 2021 Oct 20. pii: 10.1007/s11064-021-03467.
    PubMed         Abstract available

  16. XU F, Wang H, Tian J, Xu H, et al
    Down-Regulation of ID2-AS1 Alleviates the Neuronal Injury Induced by 1-Methy1-4-Phenylpyridinium in Human Neuroblastoma Cell Line SH-SY5Y Cells Through Regulating miR-199a-5p/IFNAR1/JAK2/STAT1 Axis.
    Neurochem Res. 2021;46:2192-2203.
    PubMed         Abstract available


    Neurology

  17. CHRISTINE CW, Richardson RM, Van Laar AD, Thompson ME, et al
    Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.
    Neurology. 2021 Oct 14. pii: WNL.0000000000012952.
    PubMed         Abstract available

  18. YOON SY, Park YH, Lee HJ, Kang DR, et al
    Lifestyle Factors and Parkinson Disease Risk: Korean Nationwide Cohort Study With Repeated Health Screening Data.
    Neurology. 2021 Oct 14. pii: WNL.0000000000012942.
    PubMed         Abstract available

  19. BESSE-PINOT E, Pereira B, Durif F, Fantini ML, et al
    Preoperative REM Sleep Behavior Disorder and Subthalamic Deep Brain Stimulation Outcome in Parkinson Disease 1 Year After Surgery.
    Neurology. 2021 Oct 19. pii: WNL.0000000000012862.
    PubMed         Abstract available


    Neurosci Lett

  20. BIAN K, Liu C, Wang Y, Xue Y, et al
    Orexin-B exerts excitatory effects on nigral dopaminergic neurons and alleviates motor disorders in MPTP parkinsonian mice.
    Neurosci Lett. 2021;765:136291.
    PubMed         Abstract available

  21. PANDI S, Chinniah R, Sevak V, Ravi PM, et al
    Association of HLA-DRB1, DQA1 and DQB1 alleles and haplotype in Parkinson's disease from South India.
    Neurosci Lett. 2021;765:136296.
    PubMed         Abstract available


    PLoS One

  22. MA A, Lau KK, Thyagarajan D
    Radiological correlates of vocal fold bowing as markers of Parkinson's disease progression: A cross-sectional study utilizing dynamic laryngeal CT.
    PLoS One. 2021;16:e0258786.
    PubMed         Abstract available


    Science

  23. SPIX TA, Nanivadekar S, Toong N, Kaplow IM, et al
    Population-specific neuromodulation prolongs therapeutic benefits of deep brain stimulation.
    Science. 2021;374:201-206.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: